unit state go sg websit
slightli better driven pharma fy guidanc narrow due currenc
upsid tp
nc chang
yesterday report slightli better-than-expect sale ep driven
stronger pharma sale lfl thank robust new product
growth despit declin histor drug consum impact
one-off med-tech brought surpris group slightli rais
underli fy guidanc expect less favour fx impact
pharma remain growth engin jnj sale beat consensu broadli
line estim rise lfl driven mainli sale
came consensu saw growth acceler
growth new product cancer immunolog neurosci off-set
eros compani lead histor immune-inflamm remicad total
group sale stelara inflamm benefit
new indic crohn diseas darzalex cancer came consensu due
broader use earlier stet xarelto cardiolog partner bayer us
market report slightli softer-than-expect sale continu
benefit broader use new-gener anticoagul littl surpris
medic devic divis sale grew consum
sale miss vs due one-off effect babi care
brazil adjust ep came consensu
guidanc neg impact fx underli growth slightli increas
forecast sale vs previous adjust ep
vs slightli increas underli sale growth rang
ep growth rang
consensu stand line new guidanc
hold reiter trade premium pharma sector price-to-earnings
given patent expiri despit new product launch diversif expect
organ growth sector vs compound-annual-growth-rate see limit
catalyst year although new clinic result xarelto heart failur
help market expect alreadi high super-blockbust statu
consid justifi good visibl offer three busi
societ general sg seek busi compani cover research report result investor awar
sg may conflict interest could affect object report investor consid report singl factor
make invest decis pleas appendix end report analyst certif
simplifi main product divis
medic devic diagnost
confer call feedback confid pharma remain growth driver
pharma remain growth driver sale lfl howev growth
soften due tougher comparison base impact gener procrit
tracleer us
sale divis
sale underli growth group
constant currenc exclud acquisit divestitur
ceo stress product portfolio continu benefit
broader use due rel low market penetr respect class xarelto
anticoagul space still compet old warfarin continu
declin product inflamm still penetr
zytiga prostat cancer potenti gener impact possibl entri compani
state exclud product pharma sale would grown stress
dramat depend product zytiga account divis sale
group total growth driver
us price environ ceo gave view us healthcar system highlight
fact drug account total healthcar cost medic devic
compani remain favour value-bas approach reward innov treatment base
overal benefit patient hospit payor etc would like see
transpar jnj portfolio hit neg price impact
guidanc compani lower report sale ep estim sinc
initi guidanc due lower fx impact slightli increas oper
guidanc exclud fx includ acquisit divestitur back solid
result sale growth vs previous ep growth vs
talc neg verdict ceo reiter evid safeti issu
compani product sell decad strongli believ appeal
court revert judgment mention recent press releas
med-tech sale lfl knee spine surgeri busi divis
sale low- mid-single-digit declin continu disappoint tri
reenergis despit market-specif issu portfolio
strategi group shift portfolio focu fewer area novarti
investor ask question sustain conglomer profil
manag reiter compani strategi decad stress
challeng relev strategi regular basi given activ asset
alloc strategi dispos weak busi acquisit dynam one
think remain lead diversifi healthcar group
sg cross asset research/equ constant currenc exclud acquisit
constant currenc includ acquisit divestitur
share basic year end/outstand
share price average hist yr current
valu minor
valu financi invest
new york mellon corp
depreci amortis
intang
chang work capit
flow oper activ
flow invest activ
flow financ activ
net chang cash result cf
report complet jul cet
merck co inc us buy
follow name research analyst herebi certifi certifi view express research report accur reflect
person view subject secur issuer ii part compens
relat directli indirectli specif recommend view express report florent cesped
analyst author research employ sg affili locat includ limit pari london new york
hong kong tokyo bangalor frankfurt madrid milan geneva seoul warsaw moscow
deriv target price sotp averag ev/ebita larg pharma multipl premium consum
med-tech pharma dcf lt growth lt ebita margin wacc
downsid risk non-pharma activ could becom volatil price pressur neg low single-digit impact group ebita
xarelto cardio could face pressur bms/pfe eliqui neg low single-digit impact faster eros remicad due
upsid risk remicad eros could prove slower expect posit mid single-digit impact ebita
sg equiti research rate month period
equiti rate dispers relationship
buy absolut total sharehold return forecast
month period
hold absolut total sharehold return forecast
month period
sell absolut total sharehold return forecast
appreci plu forecast cash dividend incom includ
incom special dividend paid month period
rate determin rang describ
time initi coverag chang rate subject
limit manag discret time rate may
fall outsid rang market price movement
and/or short term volatil trade pattern
interim deviat specifi rang permit
becom subject review research manag
sector weight definit month period
sector weight assign sg equiti research
strategist distinct separ sg equiti research
analyst rate base relev
overweight sector expect outperform relev
broad market benchmark next month
neutral sector expect perform in-lin relev
broad market benchmark next month
underweight sector expect under-perform relev
broad market benchmark next month
prefer least prefer stock select
cover analyst base individu analyst coverag
univers sg equiti research strategist
price inform includ report market close unless otherwis state
disclaim sourc inform exclus properti morgan stanley capit intern inc without
prior written permiss inform intellectu properti may reproduc redissemin
use creat financi product includ indic inform provid basi user assum entir
risk use made inform affili third parti involv relat comput compil
inform herebi expressli disclaim warranti origin accuraci complet merchant fit particular
purpos respect inform without limit forego event shall affili
third parti involv relat comput compil inform liabil damag kind morgan
stanley capit intern index servic mark affili similar languag may
provid approv advanc
